Status:
UNKNOWN
T2 and SeptiCyte RAPID Duration Project
Lead Sponsor:
The University of Queensland
Collaborating Sponsors:
Metro North Hospital and Health Service
Pathology Queensland
Conditions:
Bacteremia
Eligibility:
All Genders
18+ years
Brief Summary
Infection with bacteria and other germs in the blood can be deadly. How long germs stay in the blood is important for two reasons. The first is that if they stay in the blood for many days it is a sig...
Detailed Description
Bloodstream infection is highly significant and is associated with mortality rates of between 10 and 25%. For some infection types (for example, Staphylococcus aureus) a longer duration of bacteria b...
Eligibility Criteria
Inclusion
- Patients who have proven bloodstream infection with any T2-on panel pathogen (Enterococcus faecium, S. aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, Escherichia coli and Candida spp.)
Exclusion
- Palliative care approach
- Failure to give written informed consent (by patient or their legal representative)
- Polymicrobial index blood culture
Key Trial Info
Start Date :
January 11 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
August 31 2023
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT04821661
Start Date
January 11 2022
End Date
August 31 2023
Last Update
August 8 2023
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Caboolture Hospital
Brisbane, Queensland, Australia
2
Redcliffe Hospital
Brisbane, Queensland, Australia
3
Royal Brisbane and Women's Hospital
Brisbane, Queensland, Australia